NLRP3 and obesity disorder: Overall, these findings suggest that moderating obesity-driven inflammatory pathways, particularly IL-6 signaling and NLRP3 inflammasome activation, may reduce clonal expansion and mitigate the metabolic sequelae associated with CHIP.